An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials

J Virol Methods. 2007 Apr;141(1):30-3. doi: 10.1016/j.jviromet.2006.11.024. Epub 2007 Jan 8.

Abstract

We describe a method for the generation of clinical grade, live-attenuated vaccines in Vero cells entirely from cDNA plasmids. The entire electroporation procedure can be completed in less than 15 minutes and this is a significant improvement over previous lipid or electroporation based transfection techniques that also involve a heat-shock step. Importantly, the virus preparations can be generated with a minimal use of animal product derived materials, an important consideration for a vaccine candidate that is to be tested in humans. Since it is likely that all live-attenuated parainfluenza virus and pneumovirus vaccines in the future will be generated using reverse genetics, this simplified method provides guidance on how this can be achieved.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Chlorocebus aethiops
  • Clinical Trials as Topic*
  • DNA, Complementary
  • Electroporation
  • Humans
  • Kinetics
  • Parainfluenza Virus 1, Human / genetics*
  • Parainfluenza Virus 1, Human / immunology
  • Parainfluenza Virus 2, Human / genetics*
  • Parainfluenza Virus 2, Human / immunology
  • Parainfluenza Virus 3, Human / genetics*
  • Parainfluenza Virus 3, Human / immunology
  • Paramyxovirinae / genetics
  • Paramyxovirinae / immunology*
  • Plasmids
  • Recombination, Genetic
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology
  • Vero Cells
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology*

Substances

  • DNA, Complementary
  • Vaccines, Attenuated
  • Viral Vaccines